Enhanced Multi-Strategy Slime Mould Algorithm for Global Optimization Problems.

In order to further improve performance of the Slime Mould Algorithm, the Enhanced Multi-Strategy Slime Mould Algorithm (EMSMA) is proposed in this paper. There are three main modifications to SMA. Firstly, a leader covariance learning strategy is proposed to replace the anisotropic search operator in SMA to ensure that the agents can evolve in a better direction during the optimization process. Secondly, the best agent is further modified with an improved non-monopoly search mechanism to boost the algorithm's exploitation and exploration capabilities. Finally, a random differential restart mechanism is developed to assist SMA in escaping from local optimality and increasing population diversity when it is stalled. The impacts of three strategies are discussed, and the performance of EMSMA is evaluated on the CEC2017 suite and CEC2022 test suite. The numerical and statistical results show that EMSMA has excellent performance on both test suites and is superior to the SMA variants such as DTSMA, ISMA, AOSMA, LSMA, ESMA, and MSMA in terms of convergence accuracy, convergence speed, and stability.

Determining individual suitability for neoadjuvant systemic therapy in breast cancer patients through deep learning.

BACKGROUND: The survival advantage of neoadjuvant systemic therapy (NST) for breast cancer patients remains controversial, especially when considering the heterogeneous characteristics of individual patients. OBJECTIVE: To discern the variability in responses to breast cancer treatment at the individual level and propose personalized treatment recommendations utilizing deep learning (DL). METHODS: Six models were developed to offer individualized treatment suggestions. Outcomes for patients whose actual treatments aligned with model recommendations were compared to those whose did not. The influence of certain baseline features of patients on NST selection was visualized and quantified by multivariate logistic regression and Poisson regression analyses. RESULTS: Our study included 94,487 female breast cancer patients. The Balanced Individual Treatment Effect for Survival data (BITES) model outperformed other models in performance, showing a statistically significant protective effect with inverse probability treatment weighting (IPTW)-adjusted baseline features [IPTW-adjusted hazard ratio: 0.51, 95% confidence interval (CI), 0.41-0.64; IPTW-adjusted risk difference: 21.46, 95% CI 18.90-24.01; IPTW-adjusted difference in restricted mean survival time: 21.51, 95% CI 19.37-23.80]. Adherence to BITES recommendations is associated with reduced breast cancer mortality and fewer adverse effects. BITES suggests that patients with TNM stage IIB, IIIB, triple-negative subtype, a higher number of positive axillary lymph nodes, and larger tumors are most likely to benefit from NST. CONCLUSIONS: Our results demonstrated the potential of BITES to aid in clinical treatment decisions and offer quantitative treatment insights. In our further research, these models should be validated in clinical settings and additional patient features as well as outcome measures should be studied in depth.